S. Herter

发表

Pharmacodynamics of 2-{4-[(1E)-1-(Hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl}ethan-1-ol (GDC-0879), a Potent and Selective B-Raf Kinase Inhibitor: Understanding Relationships between Systemic Concentrations, Phosphorylated Mitogen-Activated Protein Kinase Kinase 1 Inh

Harvey Wong, M. Belvin, K. Hoeflich, 2009, Journal of Pharmacology and Experimental Therapeutics.

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

C. Klein, M. Bacac, C. Dumontet, 2013, Molecular Cancer Therapeutics.

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

C. Klein, M. Bacac, C. Dumontet, 2013, Molecular Cancer Therapeutics.

Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab

C. Klein, M. Lauer, S. Huber, 2019, Scientific Reports.

Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors

C. Klein, M. Hallek, L. Neumann, 2018, BioMed research international.

The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo

C. Klein, M. Bacac, M. Cragg, 2018, The Journal of Immunology.

GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity

C. Klein, M. Bacac, F. Herting, 2017, Haematologica.

Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity

C. Klein, M. Bacac, P. Umaña, 2014, The Journal of Immunology.

FcγRIIIa chromatography to enrich a-fucosylated glycoforms and assess the potency of glycoengineered therapeutic antibodies.

Petra Rueger, T. Schlothauer, P. Umaña, 2020, Journal of chromatography. A.

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.

G. Salles, L. Sehn, A. Zelenetz, 2019, Blood.

CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies

C. Klein, M. Bacac, S. Colombetti, 2018, Clinical Cancer Research.

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.

C. Klein, Claudia Ferrara Koller, M. Kubbies, 2016, Protein engineering, design & selection : PEDS.

Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy

M. Bacac, P. Umaña, S. Herter, 2015, Clinical Cancer Research.

p95HER2–T cell bispecific antibody for breast cancer treatment

C. Klein, J. Baselga, J. Tabernero, 2018, Science Translational Medicine.

Phagocytosis and Cytotoxicity Enhances Monocyte/Macrophage-Mediated Glycoengineering of Therapeutic Antibodies

C. Klein, M. Bacac, S. Herter, 2014 .

This information is current as Virus-Infected Dendritic Cells Presentation Coincide in Influenza Structure Formation and Delayed Antigen Dendritic Cell Aggresome-Like-Induced

H. Schild, J. Höhfeld, N. Hilf, 2013 .

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

C. Klein, C. Whitlow, H. Stahlberg, 2019, Science Translational Medicine.

Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation

G. Hutter, M. Bacac, S. Herter, 2022, bioRxiv.

Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining In Vitro Experiments with Systems Modeling

T. Lehr, M. Bacac, A. Walz, 2020, Molecular Cancer Therapeutics.

A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents

C. Klein, J. Kelm, M. Bacac, 2016, Cancer Immunology, Immunotherapy.

and immune effector cellmediated B-cell cytotoxicity engineering of a new type II anti-CD20 antibody with enhanced direct Increasing the efficacy of CD20 antibody therapy through the

C. Klein, M. Dyer, K. Dabbagh, 2010 .

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells

Petra C. Schwalie, D. Hanahan, C. Klein, 2022, Nature.

Cytomegalovirus Encodes a Positive Regulator of Antigen Presentation

D. Strand, P. Deegen, M. Wagner, 2006, Journal of Virology.

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

M. Belvin, S. Seshagiri, Z. Modrušan, 2009, Cancer research.

Establishing standardized immune phenotyping of metastatic melanoma by digital pathology

Vipin T. Sreedharan, Nora C. Toussaint, Christian P. Kunze, 2021, Laboratory Investigation.

GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab

C. Ries, B. Bossenmaier, P. Umaña, 2012, Clinical Cancer Research.

The Endoplasmic Reticulum-resident Heat Shock Protein Gp96 Activates Dendritic Cells via the Toll-like Receptor 2/4 Pathway*

Carsten J. Kirschning, Hans-Georg Rammensee, Hermann Wagner, 2002, The Journal of Biological Chemistry.

scifAI: Explainable machine learning for profiling the immunological synapse and functional characterization of therapeutic antibodies

C. Marr, M. Bacac, K. Essig, 2022, bioRxiv.

Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101vs. the Type I CD20 Antibodies Rituximab and Ofatumumab

C. Klein, M. Bacac, F. Herting, 2010 .

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

C. Klein, M. Dyer, K. Dabbagh, 2010, Blood.

Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.

C. Craik, N. Walker, T. Hoey, 2005, The Biochemical journal.

Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAF V600E Mutational Status and Sustained Extracellular

M. Belvin, S. Seshagiri, Z. Modrušan, 2009 .

Dendritic Cell Aggresome-Like-Induced Structure Formation and Delayed Antigen Presentation Coincide in Influenza Virus-Infected Dendritic Cells1

H. Rammensee, H. Schild, J. Höhfeld, 2005, The Journal of Immunology.

Identification of cancer patients’ needs and preferences in the development of a clinic app: a qualitative study (Preprint)

M. Boerries, J. Weis, M. Boeker, 2022, JMIR Cancer.

Pharmacodynamics of 2-{ 4-[ ( 1 E )-1-( Hydroxyimino )-2 , 3-dihydro-1 H-inden-5-yl ]-3-( pyridine-4-yl )-1 H-pyrazol-1-yl } ethan-1-ol ( GDC-0879 ) , a Potent and Selective B-Raf Kinase Inhibitor : Understanding Relationships between Systemic Concentrations , Phosphorylated Mitogen-Activated Protei

Harvey Wong, M. Belvin, K. Hoeflich, 2009 .

Pharmacodynamics of 2- ethan-1-ol (GDC-0879), a Potent and Selective B-Raf Kinase Inhibitor: Understanding Relationships between Systemic Concentrations, Phosphorylated Mitogen-Activated Protein Kinase Kinase 1 Inhibition, and Efficacy

M. Belvin, K. Hoeflich, Lesley J. Murray, 2009 .

Antitumour activity of the glycoengineered type II anti‐CD20 antibody obinutuzumab (GA101) in combination with the MDM2‐selective antagonist idasanutlin (RG7388)

C. Klein, M. Bacac, F. Herting, 2016, European journal of haematology.

Abstract 3634: A novel tumor-targeted 4-1BB agonist and its combination with T-cell bispecific antibodies: an off-the-shelf cancer immunotherapy alternative to CAR T-cells

C. Klein, M. Bacac, S. Colombetti, 2017 .

CD20 Tcb (RG6026), a Novel 2:1 T Cell Bispecific Antibody for the Treatment of B Cell Malignancies

C. Klein, M. Bacac, S. Colombetti, 2016 .

Abstract 486: Tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for the immunotherapy of cancer.

C. Klein, T. Nayak, H. Kettenberger, 2013 .

A Novel Approach for Quantifying the Pharmacological Activity of T-Cell Engagers Utilizing In Vitro Time Course Experiments and Streamlined Data Analysis

Meric A. Ovacik, C. Klein, T. Lehr, 2021, The AAPS Journal.

Correlation of dendritic cell maturation and the formation of aggregates of poly-ubiquitinated proteins in the cytosol

H. Schild, S. Herter, R. Holtappels, 2008, Medical Microbiology and Immunology.

Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.

C. Klein, U. Brinkmann, C. Ries, 2012, Archives of biochemistry and biophysics.

Obinutuzumab (GA101) More Potently Engages Phagocytic-Lineage Cells Resulting In Enhanced Monocyte and Macrophage Activity When Compared To Rituximab and Ofatumumab

C. Klein, M. Bacac, P. Umaña, 2013 .

Explainable machine learning for profiling the immunological synapse and functional characterization of therapeutic antibodies

Sayedali Shetab Boushehri, C. Marr, M. Bacac, 2023, bioRxiv.

CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

R. Houot, F. Bosch, K. Lechner, 2022, Blood.

ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma.

Vipin T. Sreedharan, Nora C. Toussaint, Christian P. Kunze, 2023, Cancer research.

Abstract LB-236: M4-3-ML2, a novel glycoengineered humanized IgG1 antibody, targeting a membrane-proximal epitope of MCSP/CSPG4 exhibits potent ADCC inductionin vitroandin vivoanti-tumoral efficacy in disseminated melanoma models

C. Klein, M. Bacac, G. Georges, 2012 .

RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies

C. Klein, M. Bacac, Claudia Ferrara Koller, 2020 .

Abstract 3629: Engineering a novel asymmetric head-to-tail 2+1 T-cell bispecific (2+1 TCB) IgG antibody platform with superior T-cell killing compared to 1+1 asymmetric TCBs

C. Klein, M. Bacac, O. Ast, 2017 .

Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101) and The novel Bcl-2 selective Inhibitor GDC-0199 Results in superior In Vitro and In Vivo Anti-tumor activity in models Of B-Cell Malignancies

C. Klein, M. Bacac, W. Fairbrother, 2013 .

S141: ELICITING ANTI-TUMOR T CELL ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH BISPECIFIC ANTIBODY-BASED COMBINATION THERAPY

M. Bacac, L. Ysebaert, A. Quillet-Mary, 2022, HemaSphere.

The PI3K Delta Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function and B Cell Depletion Mediated By Obinutuzumab (GA101) and Rituximab

C. Klein, M. Bacac, C. Quéva, 2014 .

Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo

H. Kohrt, C. Klein, D. Czerwinski, 2014 .

Abstract A245: Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, ABT-199 (GDC-0199), results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies.

C. Klein, M. Bacac, W. Fairbrother, 2013 .

Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.

C. Klein, U. Brinkmann, C. Ries, 2012, Archives of biochemistry and biophysics.

Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation

G. Hutter, M. Bacac, S. Herter, 2023, bioRxiv.

Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies

Petra C. Schwalie, M. Bacac, E. Piccione, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

scifAI: Explainable machine learning for pro�ling the immunological synapse and functional characterization of therapeutic antibodies

Sayedali Shetab Boushehri, M. Bacac, F. Schmich, 2022 .

CD20-TCB with obinutuzumab pretreatment as next generation treatment of hematological malignancies

M. Bacac, S. Colombetti, M. Perro, 2018 .

Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma.

Petra C. Schwalie, M. Bacac, A. Irmisch, 2024, Med.

Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy

M. Bacac, P. Umaña, S. Herter, 2015, Clinical Cancer Research.

Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

T. Shanafelt, M. Bacac, M. Tallman, 2023, Blood.

GA101, a novel humanized type IICD20Antibody with glycoengineered Fc and enhanced cell death induction, exhibits superior anti-tumor efficacy and superior tissue B cell depletion in vivo

C. Klein, M. Dyer, K. Dabbagh, 2007 .